Breast Cancer Therapeutic Antibody Development

Introduction of Therapeutic Antibody

Therapeutic antibodies are a type of treatment that uses antibodies to target specific proteins on cancer cells, helping the immune system recognize and destroy cancer cells. Most anti-tumor antibodies recognize antigens on the surface of tumor cells. Instead of targeting the tumor cells themselves, the antibodies recognize surface antigens that interfere with new blood vessel formation, inhibit migration, or target metalloproteinase secretion and tumor cell invasion. These antibodies can specifically target certain types of cancer, such as breast cancer. Breast cancer is a major global health challenge. It is the most common cancer in the world and the leading cause of cancer death in women.

Fig. 1. Selected approved (∗) and clinical-stage antibody-based therapeutics for oncology. (Carter PJ, et al., 2022)

Breast Cancer Therapeutic Antibody Development Services

At Alfa Cytology, we provide therapeutic antibody development services for breast cancer. Our team of experts specializes in antibody-drug conjugates drug, monoclonal antibodies and bispecific antibody development. Our services include antibody screening, optimization and production to ensure the development of high-quality therapeutic antibodies for breast cancer treatment.

• Antibody-drug Conjugates Drug

ADC combines the dual advantages of the targeting and selectivity of antibodies with those of cytotoxic drugs. It has high anti-tumor activity and can kill tumors efficiently and accurately, greatly improving the benefit-risk ratio of anti-tumor treatment.

• Monoclonal Antibody

The main functions of monoclonal antibodies are neutralization, regulation, activation of the complement pathway, and antibody-dependent cell-mediated cytotoxicity. The tumor microenvironment is key to the growth of breast cancer, which provides potential targets for monoclonal antibody therapy, especially in cases where tumor cells themselves are difficult to target, such as metastasis.

• Bispecific Antibody

Bispecific antibodies combine the specific binding domains of two different mAbs into one molecule, enabling them to interact with two different targets simultaneously, which can target tumor-associated antigens (TAAs) on BC cells while simultaneously engaging immune effector cells or blocking key signaling pathways.

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC therapeutic antibody development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.